Consequently, molecules possessing only the BH3 domain of BCL-2 proteins (termed BH3 mimetics), have received significant attention as potentially useful cancer therapeutic agents either alone or in combination with other drugs [34]. The gene discussed is BCL2; the disease is cancer.